Table 4. Time on YS110 treatment and median PFS of treated patients.
| Cohorts | Dose levels (mg kg−1) | Cancer types (n) | Median infusions N (min–max) | Median PFS days (min–max) |
|---|---|---|---|---|
| Q2W | 0.1 | Meso (3) | 3 (3) | 42 (41–42) |
| Q2W | 0.4 | Meso (2) RCC (1) | 18 (3–20) | 223 (40–273) |
| Q2W | 1.0 | Meso (2) RCC (4) | 3 (1–3) | 40 (28–59) |
| Q2W | 2.0 | Meso (6) RCC (4) | 3 (1–27) | 57 (13–399) |
| Q1W | 2.0 | Meso (3) UTC (1) | 5 (1–20) | 47 (5–184) |
| Q1W | 4.0 | Meso (3) | 4 (3–5) | 32 (22–59) |
| Q1W | 6.0 | Meso (4) | 17.5 (1–30) | 58 (15–258) |
| All | All | All | 4 (1–30) | 43 (5–399) |
Abbreviations: Meso=malignant mesothelioma; PFS=progression-free survival duration; RCC=renal cell carcinoma; UTC=urothelial carcinoma.